"The US Food and Drug Administration (FDA) is investigating the "rare but serious" risk for slowed or difficult breathing in children 17 and younger treated with the opioid analgesic tramadol.
"This risk may be increased in children tr"...
Enlon Plus Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Enlon-Plus (edrophonium chloride, USP and atropine sulfate) Injection is a combination drug containing a rapid acting acetylcholinesterase inhibitor, and an anticholinergic used as a reversal agent or antagonist of nondepolarizing neuromuscular blocking agents. It is also used adjunctively in the treatment of respiratory depression caused by curare overdosage. Common side effects include increased salivation, frequent urination, weakness, low blood pressure, and slow or irregular heart rate.
Dosages of Enlon-Plus Injection range from 0.05-0.1 mL/kg given slowly over 45 seconds to 1 minute at a point of at least 5% recovery of twitch response to neuromuscular stimulation (95% block). The dosage delivered is 0.5-1.0 mg/kg of edrophonium chloride and 0.007-0.014 mg/kg of atropine sulfate. Enlon-Plus may interact with muscle relaxants, anticholinesterase drugs, narcotics, or beta-blockers. Tell your doctor all medications and supplements you use. During pregnancy, Enlon-Plus should be used only if prescribed. Consult your doctor before breastfeeding.
Our Enlon-Plus (edrophonium chloride, USP and atropine sulfate) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Enlon Plus FDA Prescribing Information: Side Effects
Arrhythmias Frequency > 10%: junctional rhythm, bradycardia, tachycardia; Frequency 3-10%: first and second degree A-V block, P Wave changes, atrial premature contractions; Frequency 1-3%: third degree A-V block, ventricular premature contractions; Frequency less than 1%: 3 second R-R interval.
Of the patients who experienced any arrhythmias, 85% had the onset within two minutes, 74% no longer had any arrhythmias after 10 minutes. Arrhythmias related to increased vagal tone, bradycardia, second and third degree heart block respond to treatment with 0.2-0.4 mg of atropine I.V. (Bigeminy or ventricular ectopy may be treated with lidocaine 50 mg I.V.).
Adverse experiences reported for anticholinesterase agents such as edrophonium chloride, but not observed in the 235 patients studied with ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection:
Nonspecific EKG changes, fall in cardiac output leading to hypotension;
Increased tracheobronchial secretions, laryngospasm, bronchiolar constriction and respiratory muscle paralysis;
Weakness and fasciculations;
Increased urinary frequency, diaphoresis, increased lacrimation, pupillary constriction, diplopia, and conjunctival hyperemia.
Untoward reactions to atropine sulfate generally are dose-related. Individual tolerance varies greatly but systemic doses of 0.5 to 10 mg are likely to produce the following effects, which were not observed in the 235 patients treated with ENLON-PLUS (edrophonium chloride and atropine sulfate) :
Speech disturbances and restlessness with asthenia;
Flushed, dry skin, formation of a scarlatiniform rash;
Read the entire FDA prescribing information for Enlon Plus (Edrophonium Chloride and Atropine Sulfate)
Additional Enlon Plus Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.